Mapp Biopharmaceutical
Mapp Biopharmaceutical, founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin, specializes in developing pharmaceuticals for infectious diseases and biodefense, including potential treatments for Marburg virus and Sudan ebolavirus.
Company History
Mapp Biopharmaceutical was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin. The company has since been at the forefront of developing novel pharmaceuticals, with a strong focus on preventing and treating infectious diseases. Mapp Biopharmaceutical prioritizes unmet needs in global health and biodefense, demonstrating a commitment to addressing some of the most pressing medical challenges worldwide.
Founders
Mapp Biopharmaceutical was co-founded by Drs. Kevin Whaley and Larry Zeitlin. Both founders have played crucial roles in steering the company towards its mission of developing innovative pharmaceuticals for infectious diseases. Their leadership continues to drive the organization's efforts in advancing global health and biodefense initiatives.
Collaborations
Mapp Biopharmaceutical collaborates with various organizations to advance their therapeutic developments. Notably, the company partners with the Biomedical Advanced Research and Development Authority (BARDA) to develop treatments for Marburg virus, Sudan ebolavirus, and Botulinum Neurotoxin. These collaborations are pivotal in pushing forward the science needed to combat these severe infectious diseases.
Major Contracts
Mapp Biopharmaceutical secured a substantial $110 million contract from the Office of the Assistant Secretary for Preparedness and Response (ASPR) to advance the development and procurement of a therapeutic for the Sudan ebolavirus. This contract underscores the company's valuable contribution and expertise in the field of infectious disease therapeutics.
Current Developments
Mapp Biopharmaceutical is actively working on developing MBP091, a potential therapeutic for Marburg virus disease. If successful, MBP091 could become the first licensed therapeutic specifically targeting the Marburg virus, marking a significant milestone in the fight against this deadly infectious disease.